LGND News and Press, Ligand Pharmaceuticals Incorporated From 08/12/19

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and accelerating the launch of innovative therapeutics and pharmaceutical products in China, the U.S., and throughout the world, annou...

Insider buying increased significantly last week with insiders purchasing $128.07 million of stock last week compared to $75.89 million in the week prior. Selling also increased significantly with insiders selling $3.09 billion of stock last week compared to $584.61 million in the week prior. ...

Call Start: 09:00 Call End: 09:49 Ligand Pharmaceuticals Incorporated (LGND) Q2 2019 Earnings Conference Call July 30, 2019, 9:00 am ET Company Participants Todd Pettingill - Senior Director, Corporate Development & IR John Higgins - CEO Matt Foehr - COO Matt Korenberg ...

Thinly traded Ligand Pharmaceuticals ( LGND -10.7% ) slumps on more than double normal volume, albeit on turnover of only 867K shares, following its Q2 earnings release and conference call earlier today. More news on: Ligand Pharmaceuticals Incorporated, Healthcare stocks news, Stocks on...

Ligand Pharmaceuticals ( LGND ) Q2 results : Revenues: $25M (-72.2%); Royalties: $6.6M (-79.0%); Material sales: $8.5M (+11.8%); License fees, milestones and other revenues: $9.8M (-80.8%). More news on: Ligand Pharmaceuticals Incorporated, Healthcare stocks news, Earnings news and commen...

Ligand Pharmaceuticals (NASDAQ: LGND ): Q2 Non-GAAP EPS of $0.68 beats by $0.02 ; GAAP EPS of -$0.74 misses by $1.40 . More news on: Ligand Pharmaceuticals Incorporated, Earnings news and commentary, Healthcare stocks news, Read more ...

Conference Call Begins at 9:00 a.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2019, and provided an operating forecast and program updates. Ligand management will host a conferenc...

AER , AGCO , AME , AOS , ARCC , BEN , BERY , CEQP , CIGI , CMCO , CMI , CNX , CNXM , COP , CVLT , DHI , DORM , DSX , ECL , EME , EQM , ETN , EXLS , FDP , FMS , GEO , GLT , GLW , GPN , GRUB , GTX , HCA , HUBB , HUD , HUN , I , INCY , IPGP , IR , IRWD ,...

Strengthens and expands its OmniAb platform offering Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of an agreement with Ab Initio Biotherapeutics whereby Ligand will acquire Ab Initio for $12 million in cash. Ab Initio was a privately held antigen-discove...

Thoughts about performance presentation Due to a mix of personal, professional and technical reasons more than 3 weeks have passed since my last article "Do Not Sell In May (June) And Go Away; Look At These Buy Candidates" was published. There have been interesting developments both in the...